SILA123

SILA123: sourced facts only. name: "This Viewpoint describes the discovery of inhibitors targeting point mutants and the development of SILA123, a highly potent and selective type II FLT3 inhibitor." [PMID:39666851]; target: "This Viewpoint describes the discovery of inhibitors targeting point mutants and the development of SILA123, a highly potent and selective type II FLT3 inhibitor." [PMID:39666851]; developer: "Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter Street, Columbia, South Carolina 29208, United States." [PMID:39666851]; stage: "In in vivo studies, SILA-123 significantly suppressed tumor growth in allograft models, demonstrating its potential in treating resistant AML." [PMID:39666851]